Human Core Binding Factor alpha1 CBFA1/RUNX2 ELISA Kit

Instructions
Code CSB-E12935h
Size 96T,5×96T,10×96T
See More Details 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name runt-related transcription factor 2
Alternative Names Acute myeloid leukemia 3 protein ELISA Kit; Alpha subunit 1 ELISA Kit; AML3 ELISA Kit; CBF alpha 1 ELISA Kit; CBF-alpha-1 ELISA Kit; CBFA1 ELISA Kit; CCD ELISA Kit; CCD1 ELISA Kit; Cleidocranial dysplasia 1 ELISA Kit; Core binding factor ELISA Kit; Core binding factor runt domain alpha subunit 1 ELISA Kit; Core binding factor subunit alpha 1 ELISA Kit; Core-binding factor subunit alpha-1 ELISA Kit; MGC120022 ELISA Kit; MGC120023 ELISA Kit; Oncogene AML 3 ELISA Kit; Oncogene AML-3 ELISA Kit; OSF 2 ELISA Kit; OSF-2 ELISA Kit; OSF2 ELISA Kit; Osteoblast specific transcription factor 2 ELISA Kit; Osteoblast-specific transcription factor 2 ELISA Kit; OTTHUMP00000016533 ELISA Kit; PEA2 alpha A ELISA Kit; PEA2-alpha A ELISA Kit; PEA2aA ELISA Kit; PEBP2 alpha A ELISA Kit; PEBP2-alpha A ELISA Kit; PEBP2A1 ELISA Kit; PEBP2A2 ELISA Kit; PEBP2aA ELISA Kit; PEBP2aA1 ELISA Kit; Polyomavirus enhancer binding protein 2 alpha A subunit ELISA Kit; Polyomavirus enhancer-binding protein 2 alpha A subunit ELISA Kit; Runt domain ELISA Kit; Runt related transcription factor 2 ELISA Kit; Runt-related transcription factor 2 ELISA Kit; RUNX2 ELISA Kit; RUNX2_HUMAN ELISA Kit; SL3 3 enhancer factor 1 alpha A subunit ELISA Kit; SL3-3 enhancer factor 1 alpha A subunit ELISA Kit; SL3/AKV core binding factor alpha A subunit ELISA Kit; SL3/AKV core-binding factor alpha A subunit ELISA Kit
Abbreviation RUNX2
Uniprot No. Q13950
Species Homo sapiens (Human)
Sample Types serum, plasma, tissue homogenates, cell culture supernates
Detection Range 31.25 pg/mL-2000 pg/mL
Sensitivity 7.8 pg/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Epigenetics and Nuclear Signaling
Assay Principle quantitative
Measurement Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%        
Three samples of known concentration were tested twenty times on one plate to assess.    
Inter-assay Precision (Precision between assays): CV%<10%        
Three samples of known concentration were tested in twenty assays to assess.      
               
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human CBFA1 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.  
  Sample Serum(n=4)    
1:200 Average % 91    
Range % 86-95    
1:400 Average % 102    
Range % 97-107    
1:800 Average % 91    
Range % 85-97    
1:1600 Average % 97    
Range % 91-103    
Recovery
The recovery of human CBFA1 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.  
 
Sample Type Average % Recovery Range    
Serum (n=5) 95 89-98    
EDTA plasma (n=4) 97 90-100    
               
               
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.  
 
pg/ml OD1 OD2 Average Corrected    
2000 1.957 1.999 1.978 1.887    
1000 1.567 1.603 1.585 1.494    
500 1.106 1.101 1.104 1.013    
250 0.719 0.732 0.726 0.635    
125 0.407 0.412 0.410 0.319    
62.5 0.283 0.298 0.291 0.200    
31.25 0.164 0.165 0.165 0.074    
0 0.090 0.092 0.091      
Troubleshooting
and FAQs
ELISA kit FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 3-5 working days

Target Data

Function Transcription factor involved in osteoblastic differentiation and skeletal morphogenesis
Gene References into Functions
  1. these data indicated that miR-23b was involved in TNF-alpha-mediated reduction of bone marrow mesenchymal stem cell osteogenesis by targeting runx2. PMID: 29234953
  2. that cross-talk between cAMP/PKA signaling and RUNX2 promotes a malignant phenotype of glioma cells PMID: 30203400
  3. Study identified RUNX2 to be targeted by miR-217 which directly bound to RUNX2 mRNA and inhibited its expression in bladder cancer cells. Also, findings demonstrated that RUNX2 expression was upregulated by hsa_circ_0000144. Moreover, rescue assays demonstrated that RUNX2 was a downstream effector molecule of hsa_circ_0000144/miR-217 network. These results revealed the oncogenic role of RUNX2 in bladder neoplasm. PMID: 30098434
  4. In summary, these results reveal that PTHLH expression is a poor prognosis marker in head and neck squamous cell carcinoma patients, and RUNX2-PTHLH axis contributes to head and neck squamous cell carcinoma tumor growth. PMID: 28120940
  5. Knockdown of RUNX2 significantly inhibited TE-1 and EC-109 cell viability, repressed TE-1 cell migration and invasion, and increased TE-1 cell apoptosis and were associated with the activation of the PI3K/AKT and ERK pathways. PMID: 30138923
  6. Results show that RUNX2 gene silencing increased gemcitabine (GEM) sensitivity of p53mutated pancreatic cancer (PaCa) MiaPaCa2 spheres suggesting that RUNX2 is involved in PaCa-GEM resistance in presence of mutated p53. PMID: 29620279
  7. Runx2 overexpression effectively decreased TNF-alpha-induced Bax and cleaved caspase-3 expression levels PMID: 29129496
  8. RUNX2 is one of the promising molecular targets for the treatment of the patients with pancreatic cancer regardless of their p53 status[review] PMID: 29558908
  9. we identified a novel missense mutation of RUNX2 in 2 patients by Whole exome sequencing and showed potential correlations between facial phenotypes and missense mutations in Runt domain through a mini-meta analysis. PMID: 30095610
  10. Mutant Runx2 regulates amelogenesis and osteogenesis through a miR-185-5p-Dlx2 axis. PMID: 29242628
  11. Results show that RUNX2 is highly expressed in bladder cancer tissues and are negatively correlated with miR-154 levels. This is likely through miR-154 binding the 3'-UTR of RUNX2 mRNA, promoting its degradation. PMID: 29048677
  12. Results identified a novel mutation besides the previously known in one patient with cleidocranial dysplasia (CCD). G462X mutation in exon 8 is located in the C-terminus of proline/serine/threonine-rich (PST) domain. It might reduce the Runx2 transacting activity, lower the protein stability, downgrade the expression of bone marker genes, and eventually diminish osteoblast differentiation in CCD patients. PMID: 28703881
  13. Findings reveal a novel mechanism that Runx2 is transcriptionally regulated by HSP90 via the AKT/GSK-3beta/beta-catenin signaling pathway, and by which leads to apoptosis of osteosarcoma cells. PMID: 28681940
  14. Study identifies a novel missense mutation (c.895 T>C, Y299H) in exon 5 of Runx2 gene in patients with cleidocranial dysplasia (CCD). This mutation results in an amino acid change at codon 895 (P.Tyr 299 His.) from a tryptophan codon (TAT) to a histidine codon (CAT). PMID: 29058294
  15. miR-539 functions as a tumor suppressor in colorectal cance, at least in part, by targeting RUNX2. PMID: 28938522
  16. These results indicate activation of DLX5 and RUNX2 via its distal promoter represents a unique feature of GFs, and is important for ECM regulation. Down-regulation of these transcription factors in PAFs could be associated with their property to degrade collagen, which may impact on the process of periodontitis. PMID: 27645561
  17. down-regulated miR-143-5p promotes the differentiation of DPSCs into odontoblasts by enhancing Runx2 expression via the OPG/RANKL signaling pathway. PMID: 28608628
  18. Three novel mutations (R193G, 258fs, Y400X) in cleidocranial dysplasia. PMID: 28505335
  19. The Runx2 is one of the genes responsible for the pathogenesis of osteoarthritis (OA) because RUNX2 is up-regulated in chondrocytes in OA cartilage and a germline haplodeficiency or deletion of Runx2 in articular chondrocytes decelerates OA progression. PMID: 29356961
  20. application of dexamethasone reduced the expression of RUNX2 and beta-catenin in human gingiva-derived mesenchymal stem cells PMID: 28459354
  21. Runt-related transcription factor 2 (RUNX2) was directly negatively regulated by miR-203. PMID: 28525948
  22. prolactin induction of VEGF-C and Runx2 was inhibited partly by Carboxypeptidase-D inhibitors, implicating nitric oxide , produced by PRL-regulated Carboxypeptidase-D, in breast cancer progression PMID: 28364216
  23. This is the novel report describing to demonstrate that the Runx2 expression of MSC is synergistically influenced by the hydrogels elasticity and their manner of ephrinB2 immobilized. PMID: 28300720
  24. Osterix and RUNX2 are transcriptional regulators of sclerostin in human bone PMID: 27154028
  25. High RUNX2 expression is associated with invasive and metastatic potentials of gastric cancer. PMID: 27007162
  26. These findings suggest possible involvement of RUNX2-rs194328 in the etiology of NS-CL+/-P in Korean cleft-parent trios without excess parental transmission. PMID: 23909516
  27. WWOX expression was strongly inhibited in human lung cancers and lung cancer cell lines. Reintroducing WWOX into lung cancer cells inhibited their invasive phenotype through downregulating RUNX2 and its target genes including MMP-9 expression. PMID: 27834355
  28. our results strongly suggest that RUNX2 might be a key player in receptor tyrosine kinase (RTK)-based autocrine loops and a mediator of resistance to BRAF V600E inhibitors involving RTK up regulation in melanoma. PMID: 27102439
  29. Thus, WNT/beta-catenin activation is required for RUNX2 expression in at least some osteosarcoma cell types, where RUNX2 is known to promote expression of metastasis related genes. PMID: 28370561
  30. miR-105/Runx2 axis mediates FGF2-induced ADAMTS expression in osteoarthritis cartilage. PMID: 26816250
  31. regulation of gal-3 expression was strongly correlated with runx2 transcription factor in human thyroid carcinoma. PMID: 28390192
  32. Studied association of runt-related transcription factor 2 (RUNX2) polymorphisms with susceptibility and prognosis of ossification of posterior longitudinal ligament. PMID: 27704615
  33. these studies define a novel fibrinogen-alpha9beta1-SMAD1/5/8-RUNX2 signaling axis can efficiently induce osteogenic differentiation from human embryonic stem cells and induced pluripotent stem cells. PMID: 27331788
  34. Data show that BRD4 controls RUNX2 by binding to the enhancers (ENHs) and each RUNX2 ENH is potentially controlled by a distinct set of TFs and c-JUN as the principal pivot of this regulatory platform. PMID: 28981843
  35. TGF-beta1 stimulates the phosphorylation of Runx2 at three serine amino acids, and this event is required for MMP-13 expression in osteoblastic cells. PMID: 28419442
  36. TP(thymidine phosphorylase ) curbed the expression of three proteins-IRF8, RUNX2, and osterix. This downregulation was epigenetically driven: High levels of 2DDR, a product of TP secreted by myeloma cells, activated PI3K/AKT signaling and increased the methyltransferase DNMT3A's expression PMID: 27658717
  37. Overexpression of miR-196b suppressed cell viability, migration, invasion, and induced apoptosis as well as inhibited TGF-beta induced epithelial mesenchymal transition process in A549 cells. In addition, Runx2 was a putative target of miR-196b, and Runx2 silence remarkably increased cell apoptosis and abolished the promotive effects of miR-196b suppression on cell viability, migration and invasion. PMID: 28950255
  38. Runx2 promotes autophagy in metastatic breast cancer cells by increasing acetylation of alpha-tubulin sub-units of microtubules. PMID: 28345763
  39. Mutation in the RUNX2 gene is associated with acute myeloid leukemia patients with lympho-myeloid clonal hematopoiesis. PMID: 27881874
  40. present observations strongly suggest that RUNX2/mutant p53/TAp63-regulatory axis is one of the key determinants of SAHA sensitivity of p53-mutated pancreatic cancer cells PMID: 28671946
  41. All the three novel RUNX2 mutations significantly reduced the transactivation activity of RUNX2 on osteocalcin promoter. PMID: 28738062
  42. Taken together, these results identify a crucial role for the RUNX cluster in the maintenance and progression of cancer cells and suggest that modulation of the RUNX cluster using the PI polyamide gene-switch technology is a potential strategy to control malignancies. PMID: 28530640
  43. miR-466-mediated attenuation of RUNX2 as a novel therapeutic approach to regulate prostate cancer growth, particularly metastasis to bone. PMID: 28125091
  44. miR-203 has a crucial role in suppressing heterotopic ossification by directly targeting Runx2. PMID: 27787524
  45. mechanical load upregulates expression of Runx2 gene via potentiation of PC1-JAK2/STAT3 signaling axis, culminating to possibly control osteoblastic differentiation and ultimately bone formation. PMID: 27699453
  46. the Runx2 knockdown cells displayed activation of AMP-activated protein kinase (AMPKalpha), the sensor of cellular metabolism. Importantly, the Runx2 knockdown in bone-derived cells resulted in increased sensitivity to both Erk1/2 inhibition and AMPKalpha activation by PD184161 and metformin, respectively, despite increased IGF-1Rbeta and AMPKalpha levels. PMID: 26804175
  47. RUNX2 mutation disturbs the modulatory effects of dental follicle cells and periodontal ligament cells on the differentiation of osteoclasts and osteoblasts, thereby interfering with bone remodelling. These effects may contribute in part to the pathological manifestations of retention of primary teeth and delayed eruption of permanent teeth in patients with cleidocranial dysplasia. PMID: 27509906
  48. RUNX2/P57 gene expression is strongly activated, in a process that is accompanied by enrichment of activating histone marks (H3K4me3, H3ac, and H3K27ac) at the P1 promoter region, to control osteogenic lineage commitment of umbilical cord derived mesenchymal stem cells. PMID: 27689934
  49. provide evidence to show that CBX4 may serve as a tumor suppressor in colorectal carcinoma by recruiting HDAC3 to the Runx2 promoter to impede Runx2 expression PMID: 27864346
  50. Suggest an adhesion-dependent mechanism of RUNX2 for the osteotropism and bone colonization of breast cancer cells and implicate RUNX2 and integrin alpha5 as potential molecular markers for the prediction of bone metastasis. PMID: 27317874
  51. our results defined a novel pathway in which dysregulation of the RUNX2/INHBA axis due to miR-376c downregulation fosters lymph node metastasis in head and neck squamous cell carcinoma PMID: 27760788
  52. RUNX2 regulates many features of cancer cells, including cell proliferation, migration, and resistance to apoptosis. PMID: 27149112
  53. results provide evidence that WWP2 serves as a positive regulator of osteogenesis by augmenting RUNX2 transactivation in a non-proteolytic mono-ubiquitination manner. PMID: 28500134
  54. findings demonstrated that the novel c.398-399insACAGCAGCAGCAGCA mutation occurred alongside the c.411-412insG frameshift mutation, which resulted in RUNX2 truncation. RUNX2 haploinsufficiency was associated with cleidocranial dysplasia pathogenesis PMID: 28173761
  55. Here, we summarize recent knowledge about RUNX2 function, mutations and their phenotypic consequences in patients. PMID: 27272193
  56. deregulation of miR-320a/RUNX2/CYP11A1 (CYP19A1) cascade plays an important role in the development of estrogen deficiency in human cumulus granulosa cells PMID: 27965096
  57. These results indicate that VEGF-C-induced MSC osteogenesis is mediated through VEGFR2 and VEGFR3, and followed the activation of the ERK/RUNX2 signaling pathway. PMID: 28163024
  58. TRbeta suppressed Runx2 transcriptional activities, thus confirming TRbeta regulation of Runx2 at functional thyroid hormone-response elements. Significantly, these findings indicate that a ratio of the tumor-suppressor TRbeta and tumor-promoting Runx2 may reflect tumor aggression and serve as biomarkers in biopsy tissues. The discovery of this TRbeta-Runx2 signaling supports the emerging role of TRbeta as a tumor supp... PMID: 27253998
  59. Sm51 plays an important role in regulating osteogenic differentiation of mesenchymal stem cells through increasing Runx2 expression PMID: 27184949
  60. One association in the CTNNA2 gene on chromosome 2p12 [rs1567532, hazard ratio (HR) = 1.75, 95% confidence interval (CI) 1.19-2.58, P = 0.005 for homozygotes for the minor allele] and one in the last intron of the RUNX2 gene on chromosome 6p21 (rs12209785, HR = 0.88, 95% CI 0.80-0.98, P = 0.014 for heterozygotes) are of particular relevance. These loci do not coincide with those that showed the strongest associations in t PMID: 27497070
  61. miR-590-5p promotes osteoblast differentiation by indirectly protecting and stabilizing the Runx2 protein by targeting Smad7 gene expression. PMID: 27192628
  62. The results indicate that Runx2 could promote EMT and VM formation in HCC and Galectin-3 might have some function in this process. PMID: 28264434
  63. the findings of the present study provided novel insights into the control of IPO8 transcription, and may enhance understanding regarding RUNX2 regulatory mechanisms in osteoblast differentiation, bone development, and degenerative bone disease. PMID: 27277970
  64. Findings suggest thatSirt1 may regulate the expression of Runx2, which is the osteogenic transcription factor, and the production of MMP-13 from chondrocytes in OA. PMID: 27367673
  65. Runx2 is a direct downstream target of miR-455 in hepatocellular carcinoma. PMID: 27748890
  66. The predictability of Runx2 for OS in stage IV tumours differs with different ER states. PMID: 26597806
  67. the findings of this study provide evidence of the upregulation of miR628-3p in patients with atrophic non-union and that miR628-3p may exert an inhibitory effect on osteogenesis via the suppression of its target gene, RUNX2. PMID: 28035362
  68. miR-205 acts as a tumor suppressor in human osteosarcoma via directly targeting RUNX2. PMID: 27035764
  69. Study identified a sporadic CCD patient carrying a novel insertion/frameshift mutation of RUNX2. PMID: 28091408
  70. our results reveal that RUNX2 promotes hepatocellular carcinoma (HCC) cell migration and invasion by MMP9-mediated pathway, and potentially serves as a new prognostic biomarker and in therapeutic strategies for HCC. PMID: 27666365
  71. Therefore, RUNX2 haploinsufficiency impairs dental follicle-induced osteoclast formation capacity through RANKL/OPG signaling, which may be partially responsible for delayed permanent tooth eruption in cleidocranial dysplasia patients. PMID: 27068678
  72. downregulation of miR-218 may contribute to the chemoresistance of non-small cell lung cancer cells to cisplatin, which leads to upregulation of RUNX2 PMID: 26282001
  73. miR-30a play a role in suppressing proliferation, migration, and invasion of OS by targeting Runx2. PMID: 26449831
  74. our results suggest that miR-30a plays an important role to inhibit the proliferation of CS cells and presents a novel mechanism for direct miRNA-mediated suppression of Runx2 in CS. PMID: 26596830
  75. FHL2 might interact with Runx2 to mediate mesenchymal cell differentiation at the early stages of tooth development and human dental pulp cell differentiation. PMID: 26759258
  76. Preameloblast-Derived Factors Mediate Osteoblast Differentiation of Human Bone Marrow Mesenchymal Stem Cells by Runx2-Osterix-BSP Signaling. PMID: 26413977
  77. Runx2 activation by BMP signaling mediates serum deprivation triggers upregulation of hST3Gal V gene expression in MG-63 cells. PMID: 26729095
  78. GnRH regulates trophoblast invasion via RUNX2-mediated MMP2/MMP9 expression. PMID: 26660506
  79. An osteogenic medium is required for the differentiation of adul tmesenchymal stem cells, which is also under RUNX2 regulation. These findings are potentially valuable for clinical practice. PMID: 26782468
  80. results reveal the regulatory circuit between RUNX2 and SMURF1 controls RUNX2 expression and regulates odntoblastic differentiation in hDPSCs. PMID: 25260729
  81. Data suggest that RUNX2 transcription factor:TAZ transcriptional co-activator and activation of sE-Cadherin/proto-oncogene protein HER-2 signaling could be potential oncogenic pathways for breast cancer (BC) metastasis. PMID: 26320173
  82. RUNX2 mediates epigenetic regulation of the survival of p53 defective osteosarcoma cells. PMID: 26925584
  83. Studies indicate the involvement of estrogen signaling in breast cancer development and the interaction between RUNX2 and estrogen-dependent pathways can contribute to the mechanisms involved in cancer transformation. [review] PMID: 26404249
  84. that STAT-5, RUNX-2, and FGFR-2 may have a role in the progression of the mucinous phenotype, in which nuclear STAT-5 may inhibit RUNX-2 prometastatic effect PMID: 26551078
  85. Our findings suggest that suppression of miR-222-3p activity promoted osteogenic differentiation hBMSCs through regulating Smad5-RUNX2 signaling axis. PMID: 26809090
  86. Somatic transmission of Runx2 mRNAs in osteoblasts and osteosarcoma cells represents a versatile mechanism for translational rather than transcriptional induction. PMID: 26381402
  87. These results support a hypothesis whereby RUNX2-mediated repression of the SIRT6 tumor suppressor regulates metabolic pathways that promote breast cancer progression PMID: 25808624
  88. These studies establish the importance of Runx2 phosphorylation in prostate tumor growth and highlight its value as a potential diagnostic marker and therapeutic target. PMID: 25867060
  89. qPCR and in silico hybridization revealed that miR-124 and miR-155 can be directly involved in the transcriptional regulation of Runt-related transcription factor 2 (RUNX2) and receptor activator of nuclear factor kappa-B ligand (RANKL) genes. PMID: 26339601
  90. An association of SNP in RUNX2 with temporomandibular joint osteoarthritis in female Han Chinese. PMID: 25757091
  91. FGF-2 affects the mRNA and protein expression of Runx2, but not the osteocalcin protein level. PMID: 26133673
  92. Expression levels of RUNX2 and miR-10a/b individually or jointly are potential prognostic factors for predicting breast cancer recurrence. Data from in vitro studies support the notion that RUNX2 promoted cell motility by upregulating miR-10a/b PMID: 25266482
  93. The data are consistent with a model in which RUNX2 forms functional complexes with BAZ1B, RUVBL2 and INTS3 to mount an integrated response to DNA damage. PMID: 25609707
  94. up-regulation of osteonectin by oxLDL is independent of Runx2, and it may be mediated by other transcription factors PMID: 26025968
  95. miR-103a is the first identified mechanosensitive miRNA that regulates osteoblast differentiation by directly targeting Runx2 PMID: 25195535
  96. A family with an affected mother and three affected children with isolated oligo/hypodontia caused by RUNX2 duplication has been described. PMID: 25899668
  97. Runx2 provides a chemoprotective role in OS. PMID: 26528706
  98. Aberrant expression of Runx2 in aggressive tumor cells is related to the loss of specific Runx2-targeting miRNA135 and miRNA203. PMID: 25634212
  99. These findings revealed that miR3383p may act as a tumor suppressor that blocks the growth of human ovarian epithelial carcinoma through PI3K/AKT signaling pathways by targeting Runx2. PMID: 25776272
  100. RUNX2 signaling pathways with their partners TCF7 and FGFR1/2 may not be involved in CCD pathogenesis PMID: 25738174

Show More

Hide All

Involvement in disease Cleidocranial dysplasia (CLCD); Metaphyseal dysplasia with maxillary hypoplasia with or without brachydactyly (MDMHB)
Subcellular Location Nucleus
Tissue Specificity Specifically expressed in osteoblasts.
Database Links

HGNC: 10472

OMIM: 119600

KEGG: hsa:860

STRING: 9606.ENSP00000360493

UniGene: Hs.535845

Most popular with customers

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

Copyright © 2007-2018 www.cusabio.com CUSABIO TECHNOLOGY LLC All Rights Reserved. 鄂ICP备15011166号-1